Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 18/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 18/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24347495 | 0.87 | HMGCR (0.36) | HCRTR1HCRTR2ADORA2A | |
| SCHEMBL24347488 | 0.84 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL23793182 | 0.82 | ADAMTS4 (0.43) | ADORA2A | |
| SCHEMBL22242035 | 0.81 | ADORA2A (0.41) | HCRTR1HCRTR2ADORA2A | |
| SCHEMBL14508065 | 0.80 | KCNH2 (0.47) | ADORA2A | |
| SCHEMBL20890625 | 0.79 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL20890465 | 0.78 | HCRTR1 (0.42) | HCRTR1HCRTR2ADORA2A | |
| SCHEMBL536722 | 0.77 | HCRTR1 (0.41) | HCRTR1HCRTR2ADORA2A | |
| SCHEMBL4055024 | 0.76 | ADORA2A (0.42) | ADORA2A | |
| SCHEMBL536688 | 0.75 | HCRTR1 (0.42) | HCRTR1HCRTR2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | HCRTR1 1200/4885HCRTR2 839/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.